Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A2NA
|
|||
| Drug Name |
PMID27998201-Compound-11
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Metastatic cancer [ICD-11: 2D50-2E2Z] | Patented | [1] | |
| Company |
VIROBAY, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H25Cl2F4N3O4
|
|||
| Canonical SMILES |
CCC(C(=O)C(=O)NC1CC1)NC(=O)C(CC2=CC(=C(C(=C2)Cl)O)Cl)NC(C3=CC=C(C=C3)F)C(F)(F)F
|
|||
| InChI |
1S/C25H25Cl2F4N3O4/c1-2-18(21(36)24(38)32-15-7-8-15)34-23(37)19(11-12-9-16(26)20(35)17(27)10-12)33-22(25(29,30)31)13-3-5-14(28)6-4-13/h3-6,9-10,15,18-19,22,33,35H,2,7-8,11H2,1H3,(H,32,38)(H,34,37)/t18-,19-,22-/m0/s1
|
|||
| InChIKey |
HNEZRIRYWXIOJA-IPJJNNNSSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cathepsin B (CTSB) | Target's Patent Info | [1] | |
| KEGG Pathway | Lysosome | |||
| Antigen processing and presentation | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.